Ralf Gutzmer

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Eliezer M. Van Allen, Diana Miao, Bastian Schilling et al. · Science · 2015 · 3K citations · Full text

Medicine, Cancer Biology, Oncology +17

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 3K citations

Medicine, Oncology, Pharmacology +11

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015 · 2.7K citations

Medicine, Oncology, Pharmacotherapy +16

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

David Liu, Bastian Schilling, Derek Liu et al. · Nature Medicine · 2019 · 1.1K citations · Full text

Medicine, Immunology, Oncology +17